Delcath Systems, Inc.
810 Seventh Avenue
Suite 3505
New York,
NY 10019
United States - Map
Phone: 212-489-2100
Fax: 212-489-2102
Website: http://www.delcath.com
Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology. The companys proprietary technology enables the administration of high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. It is primarily involved in the development of CHEMOSAT/Melblez Kit system that administers concentrated regional chemotherapy to the liver. The company intends to sell its products directly to healthcare professionals, including medical and surgical oncologists, and interventional radiologists in the United States and internationally. It has a research and distribution agreement with Chi-Fu Trading Co., Ltd. to conduct clinical studies, as well as market, sell, and distribute the CHEMOSAT Delivery System in Taiwan and Singapore. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York. Key Statistics
| |
| | Pay | Exercised | Mr. Eamonn P. Hobbs ,
55
Chief Exec. Officer, Pres and Director | 613.00K | 0.00 | Mr. Graham G. Miao M.S., M.B.A., Ph.D.,
49
Chief Financial Officer and Exec. VP | 458.00K | 0.00 | Dr. Krishna Kandarpa M.D., PH.D.,
62
Chief Science Officer and Exec. VP of R&D | 481.00K | 0.00 | Mr. Peter J. Graham ,
46
Chief Compliance Officer, Exec. VP and Gen. Counsel | 404.00K | 0.00 | Mr. Agustin V. Gago ,
53
Consultant | 375.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.02(4.11%) 1:05PM EDT - Nasdaq Real Time Price